Article
Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis.
Pharmacogenomics - 1 Jan 2018
Ovejero-Benito María C, Prieto-Pérez Rocío, Llamas-Velasco Mar, Muñoz-Aceituno Ester, Reolid Alejandra, Saiz-Rodríguez Miriam, Belmonte Carmen, Román Manuel, Ochoa Dolores, Talegón María, Cabaleiro Teresa, Daudén Esteban, Abad-Santos Francisco
Abstract excerpt
AIM: This study evaluated the influence of pharmacogenetics in psoriatic patients treated with adalimumab and/or infliximab. MATERIALS & METHODS: Prospective observational study evaluating the association of 124 polymorphisms with the response to adalimumab or infliximab (PASI75) in patients with moderate-to-severe plaque psoriasis at 3 months (n = 95) and 6 months of treatment (n = 90). Significant SNPs for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.